Entera Bio Ltd. Ordinary Shares
ENTX
ENTX: Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
moreShow ENTX Financials
Recent trades of ENTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ENTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods and compositions for oral administration Feb. 15, 2022
-
Patent Title: Formulations for oral administration of active agents Mar. 10, 2020
-
Patent Title: Methods and compositions for oral administration Sep. 24, 2019
-
Patent Title: Methods and compositions for oral administration Jul. 03, 2018
-
Patent Title: Methods and compositions for oral administration of insulin Nov. 17, 2015
Federal grants, loans, and purchases
Followers on ENTX's company Twitter account
Number of mentions of ENTX in WallStreetBets Daily Discussion
Recent insights relating to ENTX
Recent picks made for ENTX stock on CNBC
ETFs with the largest estimated holdings in ENTX
Flights by private jets registered to ENTX